CAH

CAH

USD

Cardinal Health Inc. Common Stock

$149.530+2.250 (1.528%)

Reaalajas hind

Healthcare
Medical Distribution
Ameerika Ühendriigid

Hinnagraafik

Loading Chart...

Põhinäitajad

Turunäitajad
Ettevõtte fundamentaalnäitajad
Kauplemisstatistika

Turunäitajad

Avatud

$147.280

Kõrge

$150.120

Madal

$146.350

Maht

0.41M

Ettevõtte fundamentaalnäitajad

Turukapitalisatsioon

36.1B

Tööstusharu

Medical Distribution

Riik

United States

Kauplemisstatistika

Keskmine maht

2.59M

Börs

NYQ

Valuuta

USD

52 nädala vahemik

Madal $93.17Praegune $149.530Kõrge $150.12

Tehisintellekti analüüsiaruanne

Viimati uuendatud: 30. apr 2025
Tehisintellekti loodudAndmeallikas: Yahoo Finance, Bloomberg, SEC

CAH: Cardinal Health Inc. Common Stock - Checking the Pulse on Recent Moves

Stock Symbol: CAH Generate Date: 2025-04-30 23:07:31

Alright, let's take a look at what's been happening with Cardinal Health lately and what the signals might be telling us. Think of this as breaking down the key points without getting lost in complicated finance talk.

Recent News Buzz: Analysts Like What They See

The news flow for CAH has been pretty positive on the analyst front. We saw two separate reports from big names – UBS and B of A Securities. Both firms already had a "Buy" rating on the stock, which is a good sign because it means they thought it was worth owning even before these latest updates.

What's notable is that both analysts decided to raise their price targets. UBS bumped theirs from $150 to $160, and B of A went from $150 to $155. Raising a price target usually suggests the analyst believes the company's future prospects or current value are better than they previously thought. So, the general vibe from these experts is definitely leaning optimistic right now.

Price Check: Climbing Towards the Top

Now, let's check out what the stock price itself has been doing. Looking back over the last couple of months, CAH had a bit of a dip in early April after a nice run-up in March. But since that dip, the price has been steadily climbing back up.

In fact, the stock closed today around $141.29. That's really close to its 52-week high of $141.73. Reaching a 52-week high is often seen as a sign of strength, showing the stock is trading at its highest point in a year. Volume was also a bit higher than average today, which can sometimes indicate increased interest. The recent trend is clearly upward, recovering well from that early April wobble.

Putting It Together: What Might Be Next?

So, we've got positive analyst sentiment with raised price targets, and the stock price has been moving up, hitting levels near its yearly high. The AI prediction also points to small positive movements over the next couple of days (+1.79% tomorrow, +0.21% the day after), suggesting the upward momentum might continue short-term.

Based on this, the near-term picture seems to favor the bulls – meaning there's a positive leaning right now.

What could this mean for potential action?

  • Potential Entry Consideration: The stock is currently trading right around $141.29, very close to its 52-week high. Buying right at a high can be risky, as prices sometimes pull back after hitting such levels. The AI's suggested entry points were slightly lower, around $139.80 to $140.32. If you were considering getting in, one approach might be to see if the stock pulls back slightly towards that $140 area, which could offer a slightly better entry point than buying right at the peak. However, if the strong momentum continues, it might just keep going. It's a bit of a balancing act here.
  • Potential Exit/Stop-Loss Consideration: If you're already in, or if you decide to enter, thinking about where you might take profits or limit losses is smart. The AI suggests a potential take-profit level around $142.65, which isn't far above the current price and the 52-week high. For managing risk, a potential stop-loss level suggested is $125.87. This level is quite a bit below the current price, offering a wide buffer, but it's a point where you might decide to exit if the price unexpectedly drops significantly.

Company Context: Healthcare Backbone

Remember, Cardinal Health is a major player in healthcare distribution. They're essentially a crucial link in getting medical supplies and pharmaceuticals to hospitals and pharmacies. This means their business is tied to the overall healthcare system's activity. Analyst views and price movements often reflect expectations about how well this core business is performing and will perform. The recent positive analyst notes suggest confidence in their role and execution within this sector.


Disclaimer: This analysis is based solely on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can go down as well as up. You should always conduct your own thorough research and consider consulting with a qualified financial advisor before making any investment decisions.

Seotud uudised

Analyst Upgrades

UBS Maintains Buy on Cardinal Health, Raises Price Target to $170

UBS analyst Kevin Caliendo maintains Cardinal Health with a Buy and raises the price target from $160 to $170.

Vaata rohkem
UBS Maintains Buy on Cardinal Health, Raises Price Target to $170
Analyst Upgrades

Baird Maintains Outperform on Cardinal Health, Raises Price Target to $170

Baird analyst Eric Coldwell maintains Cardinal Health with a Outperform and raises the price target from $156 to $170.

Vaata rohkem
Baird Maintains Outperform on Cardinal Health, Raises Price Target to $170
PR Newswire

Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook

Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2025 revenues of $54.9 billion, flat to the third quarter of fiscal year 2024....

Vaata rohkem
Cardinal Health Reports Third Quarter Fiscal Year 2025 Results and Raises Fiscal Year 2025 Outlook
Analyst Upgrades

UBS Maintains Buy on Cardinal Health, Raises Price Target to $160

UBS analyst Kevin Caliendo maintains Cardinal Health with a Buy and raises the price target from $150 to $160.

Vaata rohkem
UBS Maintains Buy on Cardinal Health, Raises Price Target to $160

Tehisintellekti ennustusBeta

Tehisintellekti soovitus

Tõusev

Uuendatud kell: 2. mai 2025, 22:34

LangevNeutraalneTõusev

67.5% Kindlus

Risk ja kauplemine

Riskitase1/5
Madal risk
Sobib
Konservatiivne
Kauplemisjuhend

Sisenemispunkt

$145.23

Võta kasum

$148.49

Peata kahjum

$131.02

Põhitegurid

PDI 5.3 on MDI 4.8 kohal ADX-iga 12.7, mis viitab tõusutrendile
Praegune hind on tugitasemele ($145.42) äärmiselt lähedal, mis viitab tugevale ostuvõimalusele
Kauplemismaht on 16.4x keskmisest (24,234), mis viitab äärmiselt tugevale ostusurvele
MACD 0.1177 on signaalijoone 0.1127 kohal, mis viitab tõusvale ristumisele

Püsi kursis

Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.